Biotech | October 01, 2021
Jubilant concludes pre-IND meeting of JB1-802 with U.S. FDA
The company plans to submit the IND application by the end of 2021
The company plans to submit the IND application by the end of 2021
According to industry sales data, the 10mg strength of Afinitor generated annual sales of US $ 392 million during the twelve months ending July 2021
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
A high-value proposition recyclable film packed with industry-leading barrier and metal bond performance, sustainability quotient and U.S. FDA compliant
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval
Subscribe To Our Newsletter & Stay Updated
